GLP-1 Medications for Teens: What Parents Need to Know About Pediatric Weight Management

GLP-1 Medications for Teens: What Parents Need to Know About Pediatric Weight Management

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist

Wegovy was FDA-approved for adolescents (ages 12+) in December 2022, making it the first GLP-1 available for pediatric weight management. The STEP TEENS trial showed 16.1% weight loss vs 0.6% with placebo — dramatic results in a population with very limited treatment options. Here's what parents need to know.

Key Takeaways

• Wegovy (semaglutide) is FDA-approved for ages 12+ with obesity (BMI ≥ 95th percentile)
• STEP TEENS showed 16.1% body weight reduction in adolescents over 68 weeks
• GI side effects are similar to adults — nausea, vomiting, diarrhea, constipation
• Long-term effects on growth and development are still being studied
• Gut support is essential: GLP-1 Digestive Enzyme Companion with every meal

What the Data Shows

• STEP TEENS (semaglutide): -16.1% body weight, improved cardiometabolic markers, improved quality of life
• Side effects: 62% GI symptoms (vs 42% placebo) — nausea most common
• Discontinuation: Weight regain occurred in teens who stopped, similar to adults

Parent Considerations

1. This is not a shortcut: GLP-1s work best combined with nutrition counseling + increased activity
2. Body image: Frame treatment as health improvement, not appearance change
3. Nutrition: Teens need adequate calories, protein, and nutrients for growth — work with a pediatric dietitian
4. Protein: Low FODMAP protein powder helps meet protein needs on reduced appetite
5. GI management: GLP-1 enzymes + small frequent meals + hydration
6. Mental health monitoring: Weight loss drugs + adolescence requires regular mental health check-ins

See our muscle preservation guide and pediatric IBS guide.

This article is educational only. Pediatric GLP-1 use requires specialist evaluation and monitoring.